{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:19:44Z","timestamp":1793225984154,"version":"4.5.0"},"reference-count":57,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>It is well-known that immune checkpoint inhibitors (ICIs) can lead to uncommon but potentially life-threatening immune-related adverse events (irAEs) such as checkpoint-inhibitor pneumonitis (CIP). Early recognition, identification, and treatment are crucial with regard to decreasing toxicity from ICIs. However, there is a discrepancy in the incidence rates between the clinical trials and postmarketing studies. Several postmarketing studies have developed early detection methods and identified new risk factors in developing CIP. Thus, in this narrative review, we aim to review these incidence rates, early detection methods, and clinical risk factors for CIP in NSCLC patients, which could help to improve CIP diagnosis and management for enhanced NSCLC care. Major clinical trials and postmarketing studies of CIP incidence, early detection methods, and risk factors in NSCLC were reviewed. A wide array of potential risk factors has been implicated in the development of CIP in NSCLC, such as having preexisting interstitial lung disease, receiving PD-1 inhibitors, receiving combination ICI therapy instead of ICI monotherapy, lower pretreatment hemoglobin and albumin levels, increased baseline plasma IL-8 levels, and impaired baseline pulmonary function.<\/jats:p>","DOI":"10.3390\/curroncol33050240","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:00:32Z","timestamp":1776859232000},"page":"240","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune Checkpoint Inhibitor-Induced Pneumonitis in Non-Small Cell Lung Cancer: A Narrative Review of Incidence and Clinical Risk Factors"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4063-7300","authenticated-orcid":false,"given":"Olexiy","family":"Aseyev","sequence":"first","affiliation":[{"name":"Regional Cancer Centre, Thunder Bay Regional Health Sciences Centre, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada"},{"name":"Division of Clinical Sciences, Northern Ontario School of Medicine University, 955 Oliver Road, Thunder Bay, ON P7B 5E1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliia","family":"Zrielykh","sequence":"additional","affiliation":[{"name":"Polyclinic Department, Universal Clinic \u201cOberig\u201d, 3 Zoolohichna Street, 03057 Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2860-0636","authenticated-orcid":false,"given":"Minghan","family":"Shi","sequence":"additional","affiliation":[{"name":"Internal Medicine, Northern Ontario School of Medicine University, 955 Oliver Road, Thunder Bay, ON P7B 5E1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Filipovic","sequence":"additional","affiliation":[{"name":"Clinical Research Services, Thunder Bay Regional Health Research Institute, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada"},{"name":"Michael G. DeGroote School of Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Seymour","sequence":"additional","affiliation":[{"name":"Clinical Research Services, Thunder Bay Regional Health Research Institute, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6457-2110","authenticated-orcid":false,"given":"Rabail","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Clinical Research Services, Thunder Bay Regional Health Research Institute, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birubi","family":"Biman","sequence":"additional","affiliation":[{"name":"Division of Clinical Sciences, Northern Ontario School of Medicine University, 955 Oliver Road, Thunder Bay, ON P7B 5E1, Canada"},{"name":"Internal Medicine, Thunder Bay Regional Health Sciences Centre, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Inamura, K. (2017). Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. Front. Oncol., 7.","DOI":"10.3389\/fonc.2017.00193"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab versus neoadjuvant chemotherapy alone in early-stage NSCLC (KEYNOTE-671): A randomized, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"CheckMate 77T Investigators. Perioperative Nivolumab in Resectable Lung Cancer","volume":"16","author":"Cascone","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradio-therapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous NSCLC: 5-year out-comes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"Impower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lin, M.X., Zang, D., Liu, C.G., Han, X., and Chen, J. (2024). Immune checkpoint inhibitor-related pneumonitis: Research advances in prediction and management. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1266850"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Barr\u00f3n, F., S\u00e1nchez, R., and Arroyo-Hern\u00e1ndez, M. (2020). Risk of developing checkpoint inhibitor pneumonitis and its effect on over-all survival in non-small cell lung cancer patients previously treated with radiotherapy. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.570233"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.jtho.2018.10.007","article-title":"Checkpoint inhibitor pneumonitis\u2014Real-world incidence and risk","volume":"13","author":"Tay","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1055\/s-0036-1592298","article-title":"Immunotherapy for lung cancer: No longer an abstract concept","volume":"37","author":"Marrone","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kong, Y., Hong, L., Xu, X.C., Chen, Y.F., and Xu, J. (2024). The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small-cell lung cancer: Meta-analyses of controlled clinical trials. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0301931"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor\u2013related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Hao, Y., Zhang, X., and Yu, L. (2022). Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.911906"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.21037\/tlcr-22-168","article-title":"Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer","volume":"11","author":"Tao","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cllc.2020.04.003","article-title":"A population-based study of immunotherapy-related toxicities in lung cancer","volume":"21","author":"Sangaralingham","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non\u2013small cell lung cancer patients receiving immune checkpoint immunotherapy: Incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/1759-7714.14308","article-title":"Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis","volume":"13","author":"Yamaguchi","year":"2022","journal-title":"Thorac. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.21037\/tlcr-22-72","article-title":"Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer","volume":"11","author":"Chao","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Liu, X., Hao, N., Yang, S., Li, J., and Wang, L. (2023). Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1145143"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e1065","DOI":"10.1093\/oncolo\/oyad118","article-title":"Incidence and risk factors for pneumonitis associated with checkpoint inhibitors in advanced non-small cell lung cancer: A single center experience","volume":"28","author":"Altan","year":"2023","journal-title":"Oncologist"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cllc.2019.07.006","article-title":"Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors","volume":"20","author":"Fukihara","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00262-022-03281-7","article-title":"Risk of pneumonitis in non-small cell lung cancer patients with preexisting inter-stitial lung diseases treated with immune checkpoint inhibitors: A nationwide retrospective cohort study","volume":"72","author":"Sawa","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/1759-7714.15385","article-title":"Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer","volume":"15","author":"Sumi","year":"2024","journal-title":"Thorac. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Zeng, Z., Qu, J., and Yao, Y. (2022). Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease. BMC Pulm. Med., 22.","DOI":"10.1186\/s12890-022-02190-w"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mao, Z., Pang, G., and Huang, X. (2024). Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immu-nochemotherapy for resectable NSCLC. BMC Pulm. Med., 24.","DOI":"10.1186\/s12890-024-03041-6"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"KEYNOTE-671 Investigators. Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in meta-static non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Impower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: Results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: A randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","article-title":"First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations","volume":"18","author":"Ciuleanu","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"105071","DOI":"10.1016\/j.esmoop.2025.105071","article-title":"Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer\u2014Final analysis from phase II PACIFIC-6 trial","volume":"10","author":"Garassino","year":"2025","journal-title":"ESMO Open"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","volume":"379","author":"Luft","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagno-sis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_45","first-page":"100220","article-title":"Pretreatment lung function and checkpoint inhibitor pneumonitis in NSCLC","volume":"2","author":"Reuss","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jtho.2020.04.002","article-title":"Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: A multicenter prospective study","volume":"15","author":"Suzuki","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fujimoto, D., Kato, R., and Morimoto, T. (2016). Characteristics and prognostic impact of pneumonitis during systemic anti-cancer therapy in patients with advanced non-small-cell lung cancer. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168465"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.athoracsur.2015.03.094","article-title":"Pulmonary resection for lung cancer in patients with idiopathic interstitial pneumonia","volume":"100","author":"Omori","year":"2015","journal-title":"Ann. Thorac. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/1759-7714.12759","article-title":"Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease","volume":"9","author":"Kanai","year":"2018","journal-title":"Thorac. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2018.09.015","article-title":"Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","volume":"125","author":"Cho","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"190058","DOI":"10.1183\/16000617.0058-2019","article-title":"Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer","volume":"28","author":"Cadranel","year":"2019","journal-title":"Eur. Respir. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.7150\/jca.58851","article-title":"Laboratory parameters are possible prognostic markers in patients with advanced-stage NSCLC treated with bevacizumab plus chemotherapy","volume":"12","author":"Svaton","year":"2021","journal-title":"J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/1759-7714.13364","article-title":"Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer","volume":"11","author":"Sugano","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.21037\/tlcr-22-732","article-title":"Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: A retrospective multi-center cohort study","volume":"11","author":"Lin","year":"2022","journal-title":"Transl. Lung. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2634444","DOI":"10.1080\/07853890.2026.2634444","article-title":"Integrated machine learning risk model for predicting radiation pneumonitis in lung cancer patients with interstitial lung disease","volume":"58","author":"Lu","year":"2026","journal-title":"Ann. Med."},{"key":"ref_57","unstructured":"National Comprehensive Cancer Network (2025). Management of Immune Checkpoint Inhibitor-Related Toxicities, Dove Medical Press. NCCN Guidelines; Version 1.2026."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/240\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:47:49Z","timestamp":1776862069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":57,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["curroncol33050240"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33050240","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]}}}